畢業(yè)于北京大學(xué)醫(yī)學(xué)部，2012-8在北京大學(xué)腫瘤醫(yī)院工作至今。擅長晚期肺癌的綜合治療及臨床研究的相關(guān)診療等。作為主要研究者參與多項(xiàng)國內(nèi)外臨床研究。目前擔(dān)任中國老年學(xué)和老年醫(yī)學(xué)學(xué)會腫瘤康復(fù)分會精準(zhǔn)醫(yī)療專家委員會委員，北京腫瘤防治研究會肺癌分委會委員，北京癌癥防治學(xué)會教育專委會委員。以第一作者發(fā)表SCI及國內(nèi)核心期刊論文近十篇。

出診時(shí)間：周一、二、三上午線上門診，周五上午線下門診

發(fā)表論文

工作以來，以第一作者發(fā)表多篇SCI論文，部分如下：

1) Wang Y, Lian B, Si L, Mao L, Chi Z, Sheng X, Kong Y, Wang X, Bai X, Yan X, Li S, Tang B, Dai J, Zhou L, Wei X, Cui C, Guo J. Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III. European Journal of Cancer. 2022 Nov;175:196-203. IF 10.002

2) Wang Y, Lian B, Si L, Chi Z, Sheng X, Wang X, Mao L, Tang B, Li S, Yan X, Bai X, Zhou L, Cui C, Guo J. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology. 2021 Sep;147(9):2731-2740. IF 4.322

3) Wang Y, Nie J, Dai L, Hu W, Zhang J, Chen X, Ma X, Tian G, Han J, Han S, Wu D, Long J, Zhang Z, Fang J. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. Cancer Immunology, Immunotherapy. 2022 Feb;71(2):267-276. IF 6.63

4) Wang Y, Zhang X, Tian D, Han S, Zhang J, Nie J, Dai L, Hu W, Chen X, Ma X, Tian G, Wu D, Zhang Z, Long J, Fang J. Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study. Cancer Medicine. 2023 Feb;12(3):2303-2311. IF 4.711

5) Wang Y, Nie J, Dai L, Hu W, Chen X, Han J, Ma X, Tian G, Han S, Long J, Zhang Z, Fang J. Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. Thoracic Cancer. 2019 Jan;10(1):17-23. IF 3.223